15-PGDH Modulator Compounds for Selective Prostaglandin Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for modulating short-chain dehydrogenase (SCD) activity, particularly 15-PGDH, are limited in effectively addressing disorders related to prostaglandin regulation, such as colon tumors and thrombin-mediated cell death, due to the lack of specific inhibitors and activators.
Innovation Solution
Development of compounds with specific structures that act as SCD inhibitors or activators, specifically targeting 15-PGDH, to modulate prostaglandin levels and treat associated disorders by inhibiting or enhancing enzyme activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to modulate SCD activity, then general prostaglandin regulation is achieved, but specific disorders like colon tumors and thrombin-mediated cell death are not effectively treated
Solution Approach 1:
The patent introduces specific compound intermediaries (formula I and formula II structures) that mediate between the therapeutic goal and the target enzyme 15-PGDH. These compounds act as selective inhibitors or activators of 15-PGDH, providing disorder-specific treatment while maintaining general prostaglandin regulation. The compounds serve as molecular mediators that bridge the gap between broad therapeutic approaches and specific disease targets.
2Reliability
If 15-PGDH activity is inhibited to increase prostaglandin levels, then beneficial effects in conditions like colon tumors are achieved, but off-target effects on other dehydrogenases may occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (formula I and II) that confer selective binding to 15-PGDH. The molecular structure includes specific functional groups and spatial arrangements that match the active site geometry of 15-PGDH, ensuring localized action on this specific enzyme while sparing other dehydrogenase enzymes. This structural specificity minimizes off-target effects while maintaining therapeutic benefit.
3Adaptability or versatility
If broad SCD inhibitors are used, then multiple dehydrogenase activities are modulated, but the desired specific prostaglandin regulation is not achieved
Solution Approach 1:
The patent employs parameter changes by modifying molecular structure parameters (substituents R1-R7 in formulas I and II) to optimize selectivity for 15-PGDH. By systematically varying structural parameters such as substituent types, positions, and configurations, the compounds achieve enhanced binding affinity and specificity for 15-PGDH while maintaining the ability to regulate prostaglandin levels. This parameter optimization resolves the contradiction between broad adaptability and specific enzyme modulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively increase or decrease prostaglandin levels, providing therapeutic benefits in conditions like colon tumors and thrombin-mediated cell death, and are suitable for administration in tissues or blood.
Implementation Method 1
Short-chain dehydrogenases (SCDs) are a family of dehydrogenases that share only 15% to 30% sequence identity, with similarity predominantly in the coenzyme binding domain and the substrate binding domain. The SCD, 15-hydroxy-prostaglandin dehydrogenase (15-PGDH)... catalyzing oxidation of PGE2 to 15-keto-prostaglandin E2
Data Source
AI summary
Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.